Advancing Anticoagulation Care
Expert Insights
To advance anticoagulation care, Boehringer Ingelheim developed Praxbind®(idarucizumab), a specifically targeted reversal agent to dabigatran (Pradaxa®), for use in rare emergency situations when patients require urgent reversal of its anticlotting effect.
Here leading experts provide their insights on the next generation in anticoagulation care from newer anticoagulant treatments for stroke prevention to the reversal agent (Praxbind®) and its role in the emergency room.
Explore the impact these new treatments are having on patients and physicians alike.
|
“The development of Praxbind® reinforces Boehringer Ingelheim’s ongoing commitment to scientific innovation within the anticoagulation field.” | 
|
“Despite the impressive safety and improvements of the NOACs over warfarin, this increased security blanket is an important psychological advantage for physicians and patients.” |